spondyloarthropathy: A group of inflammatory rheumatic diseases associated with arthritis and enthesitis, and often involving the axial skeleton. The most common form of spondyloarthritis is ankylosing spondylitis. Other forms include axial spondyloarthritis, peripheral spondyloarthritis, reactive arthritis, psoriatic arthritis/spondylitis and enteropathic arthritis/spondylitis.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519972 |
1. Apply sex-specific ruleNone |
519972 |
2. Check conditionsNone |
519972 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters: 2 out of 7 registries used, show all original rules. |
117 |
4. Check minimum number of eventsNone |
117 |
5. Include endpointsNone |
117 |
6. Filter based on genotype QC (FinnGen only) |
113 |
Control definitions (FinnGen only)
- Control exclude
- M13_DORSOPATHY
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- M46
- Name in latin
- Osteomyelitis vertebrae
Similar endpoints
↥List of similar endpoints to
Osteomyelitis of vertebra
based on the number of shared cases.
Similar with more cases:
- Autoimmune diseases related-to ILD
- Spondylopathies
- Dorsopathies
- Diseases of the musculoskeletal system and connective tissue
- Any operation in hilmo
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 937 | 363 | 565 |
| Only index persons | 806 | 323 | 483 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.01 | 0.01 | 0.02 |
| Only index persons | 0.02 | 0.01 | 0.02 |
| Median age at first event (years) | |||
| Whole population | 63.49 | 65.55 | 62.11 |
| Only index persons | 62.54 | 64.59 | 61.16 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 113 | 40 | 73 |
| Unadjusted period prevalence (%) | 0.03 | 0.01 | 0.03 |
| Median age at first event (years) | 63.52 | 59.04 | 65.98 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 117
- Matched controls
- 1170
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
M46.2
ICD-10 Finland
Osteomyelitis of vertebra
+∞
168.9
117
*
M46.3
ICD-10 Finland
Infection of intervertebral disc (pyogenic)
+∞
37.5
34
*
M46.4
ICD-10 Finland
Discitis, unspecified
+∞
36.4
33
*
NA3CG
NOMESCO Finland
Lumbar spine extensive MRI examination with high intensity magnet
227.0
33.6
33
*
A41.0
ICD-10 Finland
Sepsis due to Staphylococcus aureus
90.7
30.8
33
5
M54.9
ICD-10 Finland
Dorsalgia, unspecified
14.7
30.7
31
28
J01MA12
ATC
levofloxacin; systemic
7.0
24.2
55
132
NA3AA
NOMESCO Finland
Lumbar spine X-ray examination without contrast
27.0
23.3
32
16
NA3BG
NOMESCO Finland
Lumbar spine MRI examination with high intensity magnet
94.3
21.6
23
*
N03AX16
ATC
[U] pregabalin
6.8
21.3
44
95
N02AE01
ATC
buprenorphine; parenteral, sublingual, transdermal
8.8
20.6
30
44
M48.0
ICD-10 Finland
Spinal stenosis
56.6
20.0
23
5
L28
ICPC
Limited function/disability (L)
6.8
20.0
40
83
A49.9
ICD-10 Finland
Bacterial infection, unspecified
6.5
18.9
39
83
M54.5
ICD-10 Finland
Low back pain
5.6
18.8
54
156
J01FF01
ATC
clindamycin; systemic
5.3
18.0
60
195
N06AX21
ATC
duloxetine; oral
8.9
17.2
24
33
J04AB02
ATC
rifampicin; systemic
196.9
17.0
17
*
N02AX02
ATC
tramadol; systemic, rectal
5.1
16.9
73
289
M51.1
ICD-10 Finland
Lumbar and other intervertebral disc disorders with radiculopathy
34.0
15.8
20
7
M54.4
ICD-10 Finland
Lumbago with sciatica
7.0
14.9
26
46
N02AA05
ATC
oxycodone; systemic
5.0
14.8
42
117
M51.3
ICD-10 Finland
Other specified intervertebral disc degeneration
61.2
14.2
16
*
GD1AA
NOMESCO Finland
Thorax X-ray examination
4.6
13.9
82
393
M46.9
ICD-10 Finland
Inflammatory spondylopathy, unspecified
+∞
13.8
13
*
A41.9
ICD-10 Finland
Sepsis, unspecified
15.6
13.6
22
17
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
4.3
13.3
52
184
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
4.5
12.0
38
114
FM1EE
NOMESCO Finland
Extensive structural and functional ultrasound examination of heart
4.0
11.9
52
197
UKC02
NOMESCO Finland
Cystoscopy
4.3
11.0
36
110
N03AX12
ATC
[U] gabapentin; oral
5.2
11.0
26
61
ABC36
NOMESCO Finland
Decompression of lumbar nerve roots
+∞
10.6
10
*
L03
ICPC
Low back symptom/complaint
4.0
10.3
38
126
FM1BE
NOMESCO Finland
Cardiac ultrasound examination through oesophagus
8.2
9.9
22
32
NA2BG
NOMESCO Finland
Thoracal spine MRI examination with high intensity magnet
33.1
9.6
12
*
ZXD05
NOMESCO Finland
Urgent procedure
3.4
9.5
53
229
G06.1
ICD-10 Finland
Intraspinal abscess and granuloma
+∞
9.5
9
*
X59
ICD-10 Finland
Exposure to unspecified factor
4.0
9.3
32
100
C03CA01
ATC
furosemide; systemic
3.3
9.2
54
240
UJF32
NOMESCO Finland
Coloscopy
3.5
9.1
43
167
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
4.3
8.9
27
77
TPH04
NOMESCO Finland
Cathetrisation of vein
3.6
8.8
38
139
GD1PA
NOMESCO Finland
X-ray examination of the lungs in one projection
4.5
8.6
24
64
A06AD11
ATC
lactulose; oral
4.1
8.6
27
79
SPAT1262
SPAT
Handing over of treatment supplies
3.7
8.5
33
112
M50.1
ICD-10 Finland
Cervical disc disorder with radiculopathy
+∞
8.4
8
*
N02AA59
ATC
codeine, combinations excl. psycholeptics; systemic
3.1
8.3
60
297
NA2AA
NOMESCO Finland
Thoracal spine X-ray examination without contrast
18.9
8.3
12
7
A40.8
ICD-10 Finland
Other streptococcal sepsis
18.9
8.3
12
7
NK6CT
NOMESCO Finland
Bone biopsy with CT guidance
36.1
8.2
10
*
NA3DG
NOMESCO Finland
Lumbar spine very extensive MRI examination with high intensity magnet
36.1
8.2
10
*
TPH15
NOMESCO Finland
Insertion of central venous catheter through external or internal jugular vein
7.3
8.1
19
30
WX408
NOMESCO Finland
General anesthesy, balanced
3.3
8.1
42
171
J18.9
ICD-10 Finland
Pneumonia, unspecified
3.2
8.1
47
205
I50.9
ICD-10 Finland
Heart failure, unspecified
3.6
7.8
32
112
NA1CG
NOMESCO Finland
Cervical spine extensive MRI examination with high intensity magnet
48.3
7.8
9
*
N10
ICD-10 Finland
Acute tubulo-interstitial nephritis
3.8
7.8
28
90
NA7CG
NOMESCO Finland
Spine and spinal cord extensive MRI examination with high intensity magnet
27.1
7.7
10
*
KH1AE
NOMESCO Finland
Urinary tract ultrasound examination
7.1
7.6
18
29
A46
ICD-10 Finland
Erysipelas
3.6
7.6
29
97
R50.9
ICD-10 Finland
Fever, unspecified
3.6
7.5
30
103
M47.2
ICD-10 Finland
Other spondylosis with radiculopathy
85.3
7.5
8
*
ZXE00
NOMESCO Finland
One hour or less
2.9
7.5
57
287
SPAT1230
SPAT
Aid fitting and borrowing and monitoring of use
3.7
7.4
27
87
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
3.3
7.4
34
128
L08.9
ICD-10 Finland
Local infection of skin and subcutaneous tissue, unspecified
17.1
7.4
11
7
TPH20
NOMESCO Finland
Insertion of central venous catheter through subclavian or brachiocephalic vein
9.2
7.1
14
17
205
Kela drug reimbursment
Chronic hypertension
2.9
7.0
46
212
JN1AE
NOMESCO Finland
Ultrasound examination of upper part of abdomen
4.5
6.9
18
45
NA1AA
NOMESCO Finland
Cervical spine X-ray examination without contrast
18.0
6.9
10
6
J01CF02
ATC
cloxacillin; systemic
18.0
6.9
10
6
NA2CG
NOMESCO Finland
Thoracal spine extensive MRI examination with high intensity magnet
42.6
6.8
8
*
J01XX08
ATC
linezolid; systemic
42.6
6.8
8
*
M03BX02
ATC
tizanidine; oral
2.8
6.8
73
433
SPAT1222
SPAT
Counselling/guidance promoting independent living
3.6
6.5
25
83
WYA30
NOMESCO Finland
Treatment of a patient needing special arrangements
4.6
6.3
16
39
7227C
ICD-9 Finland
Intervertebral disk disorders, Intervertebral disk disorder with myelopathy[SYNDROMA ISCHIADICUM]
+∞
6.3
6
*
NA1DG
NOMESCO Finland
Cervical spine very extensive MRI examination with high intensity magnet
+∞
6.3
6
*
NA3CM
NOMESCO Finland
Lumbar spine extensive MRI examination with 3 Tesla magnet
+∞
6.3
6
*
Z01.8
ICD-10 Finland
Other specified special examinations
3.1
6.3
31
121
N17.9
ICD-10 Finland
Acute renal failure, unspecified
7.4
6.3
14
21
JN3AD
NOMESCO Finland
Abdominal CT examination
3.9
6.2
20
59
I48
ICD-10 Finland
Atrial fibrillation and flutter
2.8
6.2
39
175
AA1AD
NOMESCO Finland
CT of head and brain
2.8
6.1
41
190
N39.0
ICD-10 Finland
Urinary tract infection, site not specified
3.5
6.0
23
76
N18.8
ICD-10 Finland
Other chronic renal failure
8.8
6.0
12
15
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
28
50
7.05
15.96
7.5
3.3
2.44
2.63
mmol/l
0.08
23
40
84
437
4.27
12.02
23.0
12.3
1.29
1.31
inr
0.08
39
133
60
254
3.80
11.56
3.0
2.1
257.69
296.89
u/l
0.13
54
236
21
29
8.58
9.75
2.0
2.5
—
—
—
0
0
37
125
3.87
9.71
4.1
2.1
20.44
22.70
%
0.45
31
114
16
13
14.03
9.70
10.9
6.3
13.19
9.82
mg/l
1.61
16
13
77
421
3.42
9.29
17.4
6.6
1.20
1.21
mmol/l
0.75
63
363
22
52
4.98
9.12
1.8
1.2
—
—
—
0
0
15
14
12.09
8.58
1.5
1.1
—
—
—
0
0
48
211
3.16
8.16
3.2
1.9
3.31
3.06
mg/l
0.25
38
182
16
20
9.08
7.90
3.7
1.3
—
—
—
0
0
13
11
13.11
7.79
3.9
1.5
1.72
1.65
mmol/l
0.08
13
11
16
21
8.64
7.69
7.0
2.6
24.86
25.90
mmol/l
0.23
16
21
16
21
8.64
7.69
6.9
2.6
7.27
7.36
kpa
0.05
16
21
30
102
3.61
7.65
8.8
2.8
—
—
—
0
0
39
157
3.23
7.62
3.5
1.8
—
—
—
0
0
63
334
2.92
7.53
5.5
2.8
—
—
—
0
0
42
178
3.12
7.51
2.2
1.8
599.06
423.14
pmol/l
1.75
32
145
50
236
2.95
7.37
4.3
2.8
10893.79
4007.17
umol/l
0.28
42
206
36
141
3.24
7.33
12.2
5.0
1.11
1.06
mmol/l
0.41
36
128
39
163
3.09
7.10
2.6
1.5
1276.04
1127.30
nmol/l
0.46
29
125
23
69
3.90
6.98
5.0
3.3
1.19
1.23
mmol/l
2.68
23
60
63
347
2.77
6.82
4.5
2.3
173.46
168.65
ug/l
0.06
58
315
12
12
10.98
6.71
4.3
1.8
57.25
60.67
%
0.41
12
12
80
519
2.71
5.95
17.6
10.2
4.21
4.23
e9/l
0.03
75
460
11
12
9.98
5.93
4.2
1.8
3.98
4.76
e9/l
0.50
11
12
62
361
2.53
5.71
7.8
3.8
49.50
39.30
ng/l
0.37
52
263
20
63
3.62
5.63
2.2
1.5
—
—
—
0
0
13
22
6.50
5.40
1.6
1.6
—
—
—
0
0
34
151
2.76
5.40
2.6
1.7
32.30
29.31
s
2.16
34
146
14
27
5.74
5.28
2.5
1.8
—
—
—
0
0
16
47
3.79
4.95
2.0
2.1
1.67
1.57
g/l
0.11
16
41
12
21
6.24
4.90
2.7
1.8
—
—
—
0
0
9
10
9.63
4.88
3.1
1.2
—
—
—
0
0
13
26
5.49
4.80
2.5
1.8
—
—
—
0
0
40
203
2.47
4.79
1.9
1.5
15.96
20.50
nmol/l
1.09
34
172
7
5
14.76
4.63
3.4
1.2
—
—
—
0
0
55
326
2.30
4.61
3.1
2.3
72.49
76.83
nmol/l
0.48
48
286
11
19
6.27
4.56
1.2
1.4
—
—
—
0
0
62
388
2.27
4.55
4.0
2.5
—
—
—
0
0
11
21
5.66
4.26
1.1
2.2
—
—
—
0
0
25
107
2.70
4.19
1.2
1.2
1.04
7.84
u/ml
—
7
46
10
18
5.97
4.07
2.7
1.8
—
—
—
0
0
7
7
10.53
4.06
3.7
1.1
—
—
—
0
0
7
7
10.53
4.06
1.1
1.1
—
—
—
0
0
14
38
4.04
3.96
2.9
2.0
—
—
—
0
0
13
33
4.30
3.94
2.6
1.6
—
—
—
0
0
9
15
6.40
3.90
2.9
1.8
—
—
—
0
0
55
344
2.13
3.88
2.2
1.9
93.86
89.19
pmol/l
0.21
28
185
9
16
5.99
3.74
3.1
1.4
—
—
—
0
0
8
13
6.51
3.56
1.6
1.2
—
—
—
0
0
23
103
2.53
3.50
9.8
5.3
-0.53
1.17
mmol/l
0.58
18
87
37
207
2.15
3.40
4.2
2.3
—
—
—
0
0
9
19
5.04
3.31
1.0
1.3
—
—
—
0
0
9
19
5.04
3.31
2.9
1.7
—
—
—
0
0
9
19
5.04
3.31
1.3
1.1
—
—
—
0
0
46
283
2.03
3.28
6.3
3.6
3193.29
1537.02
ng/l
0.70
41
241
7
11
6.68
3.23
1.1
1.5
—
—
—
0
0
5
5
10.36
3.00
1.2
1.0
184.60
102.48
iu/ml
—
5
5
5
5
10.36
3.00
4.4
1.2
—
—
—
0
0
60
417
1.90
2.92
6.4
3.4
0.00
0.00
estimate
-0.00
23
82
6
9
6.95
2.90
1.0
1.7
5.55
5.00
mg/l
—
6
9
8
18
4.69
2.85
3.1
1.7
—
—
—
0
0
5
6
8.63
2.77
4.4
1.2
—
—
—
0
0
5
6
8.63
2.77
1.0
1.2
—
—
—
0
0
14
56
2.70
2.64
10.7
6.5
92.88
94.35
%
0.68
14
56
59
418
1.83
2.62
7.9
4.8
0.00
0.00
estimate
-0.00
20
80
8
20
4.21
2.62
2.1
1.2
—
—
—
0
0
37
227
1.92
2.57
7.4
3.5
0.00
0.00
estimate
-0.00
19
79
24
126
2.14
2.54
1.3
1.1
15.33
31.67
iu/ml
—
6
44
59
423
1.80
2.49
6.4
3.5
0.00
0.00
estimate
-0.00
21
73
104
898
2.42
2.43
51.5
13.6
27.93
26.13
mg/l
0.23
96
711
7
17
4.31
2.40
1.9
1.8
—
—
—
0
0
21
107
2.17
2.39
3.8
1.8
—
—
—
0
0
21
108
2.15
2.34
3.7
1.7
—
—
—
0
0
31
187
1.89
2.24
4.1
3.0
1013.75
214.76
ng/l
0.60
24
151
48
335
1.73
2.15
6.9
3.6
—
—
—
0
0
7
20
3.65
2.09
1.3
2.0
—
—
—
0
0
7
20
3.65
2.09
1.3
2.0
—
—
—
0
0
6
15
4.15
2.06
1.5
1.1
—
—
—
0
0
13
59
2.35
1.92
2.9
1.7
—
—
—
0
0
76
617
1.66
1.82
4.2
3.3
14.90
14.93
pmol/l
0.03
68
539
94
809
1.82
1.81
5.0
4.0
2.19
2.01
mu/l
0.47
83
710
10
41
2.57
1.69
5.8
1.3
—
—
—
0
0
6
19
3.27
1.68
1.5
1.3
—
—
—
0
0
25
155
1.78
1.64
1.4
1.3
1.25
0.79
u/ml
—
8
37
65
518
1.57
1.60
3.4
2.7
—
—
—
0
0
5
15
3.43
1.54
1.8
1.1
—
—
—
0
0
40
302
1.49
1.19
6.1
3.8
44.71
10.25
mg/mmol
1.28
28
202
5
21
2.44
1.10
1.0
1.1
—
—
—
0
0
5
21
2.44
1.10
1.2
1.2
—
—
—
0
0
98
891
1.62
1.09
41.3
13.0
73.94
79.11
ml/min/173m2
1.11
93
722
106
984
1.82
1.07
50.2
16.5
106.34
82.33
umol/l
1.72
106
984
55
449
1.42
1.07
4.4
5.0
1.65
3.21
ug/l
1.23
46
401
105
974
1.76
1.04
52.5
15.4
139.32
139.59
mmol/l
0.59
105
941
105
975
1.75
1.02
53.4
15.6
4.05
3.99
mmol/l
1.80
105
940
8
43
1.92
0.89
2.4
2.8
4.22
4.45
pmol/l
—
8
37
30
231
1.40
0.79
1.7
1.6
1.64
1.32
mmol/l
0.88
22
190
12
76
1.65
0.75
3.0
2.6
6.31
10.41
ug/l
0.51
12
68
7
42
1.71
0.70
7.0
3.0
1.56
1.41
%
—
7
42
5
28
1.82
0.67
1.2
1.3
—
—
—
0
0
96
899
1.38
0.61
5.6
4.5
6.30
6.07
mmol/l
0.57
83
801
92
860
1.33
0.56
8.7
6.0
43.09
40.46
mmol/mol
1.21
84
784
5
35
1.45
0.40
1.0
1.3
—
—
—
0
0
92
886
1.18
0.25
4.9
3.9
1.34
1.26
mmol/l
0.48
81
794
23
262
0.85
0.24
2.2
3.0
0.66
0.86
ug/l
0.85
15
178
39
358
1.13
0.21
2.5
4.2
22.53
22.41
%
0.02
20
182
9
110
0.80
0.21
7.3
7.9
—
—
—
0
0
0
13
0.00
0.21
0.0
1.2
—
7.99
—
0
8
6
47
1.29
0.21
1.5
2.2
—
—
—
0
0
6
52
1.16
0.19
1.2
2.5
—
—
—
0
0
8
77
1.04
0.07
2.0
1.5
—
—
—
0
0
13
120
1.09
0.05
1.2
1.4
—
—
—
0
0
91
916
0.97
0.00
5.5
4.3
1.33
1.42
mmol/l
1.25
80
825
94
942
0.99
0.00
5.8
4.8
2.40
2.67
mmol/l
2.02
81
847
0
5
0.00
0.00
0.0
1.6
—
—
—
0
0
0
5
0.00
0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
0.00
0.0
1.6
—
—
—
0
0
0
5
0.00
0.00
0.0
1.6
—
—
—
0
0
0
5
0.00
0.00
0.0
1.4
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.5
—
—
—
0
0
92
920
1.00
-0.00
5.6
4.3
4.26
4.52
mmol/l
1.55
81
837
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
2.8
—
73.67
—
0
6
0
6
0.00
-0.00
0.0
1.3
—
1099.83
—
0
6
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint M13_OSTEOMYELVERTEB and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| M13_OSTEOMYELVERTEB | 1.996 [1.5, 2.65] | < 0.001 |
| Birth year | 0.99 [0.98, 1.0] | 0.024 |
During the follow-up period (1.1.1998 — 31.12.2019), 121 out of 325 females with M13_OSTEOMYELVERTEB died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| M13_OSTEOMYELVERTEB | 2.433 [1.84, 3.22] | < 0.001 |
| Birth year | 0.985 [0.98, 0.99] | 0.002 |
During the follow-up period (1.1.1998 — 31.12.2019), 201 out of 503 males with M13_OSTEOMYELVERTEB died.
Mortality risk
Mortality risk for people of age
years, who have M13_OSTEOMYELVERTEB.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.15% | 0.363% |
| 5 | 0.982% | 2.718% |
| 10 | 2.528% | 6.78% |
| 15 | 4.728% | 12.398% |
| 20 | 8.398% | 20.461% |
Relationships between endpoints
↥Index endpoint: M13_OSTEOMYELVERTEB – Osteomyelitis of vertebra
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data